← Evidence map

ArticleFrontiers in oncology2026

Safety recommendations for ALK tyrosine kinase inhibitors in non-small cell lung cancer: evidence from FAERS and CVARDD real-world databases.

Yuanyuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Safety recommendations for ALK tyrosine kinase inhibitors in non-small cell lung cancer: evidence from FAERS and CVARDD real-world databases. | OpenQuestion